Tuberculosis (TB) surveillance is a vital step toward eradicating a disease that is the second leading infectious disease killer worldwide, behind COVID-19.1 Caused by bacteria in the Mycobacterium tuberculosis complex (MTBC), which includes Mycobacterium tuberculosis (Mtb), TB is a treatable disease but multidrug-resistant TB (MDR-TB) remains a public health crisis and a health security threat.1 Genomic-based TB surveillance can support public health officials in:
The discriminatory power of next-generation sequencing enables outbreaks to be addressed with greater speed and confidence.
Drug-resistant TB (DR-TB) is an MTBC that is resistant to one or more anti-TB drugs and represents a major challenge in controlling the pathogen’s diagnosis, treatment, and eradication.2 Detecting and characterizing these strains are therefore a vital part of disease surveillance.
Next-generation sequencing (NGS)-based solutions, such as targeted NGS (tNGS) and whole-genome sequencing (WGS), offer key advantages in detecting DR-TB and are detailed below.
This comprehensive infographic displays information about TB drugs, treatment, surveillance methods, and more facts and figures in a visual format.
The MiSeq benchtop sequencer enables targeted and microbial genome applications, with high-quality sequencing, simple data analysis, and cloud storage.
Explore how the MiniSeq System can harness the power of NGS in an accessible sequencing format perfect for your benchtop. Streamlined and cost-efficient for rapid sequencing of DNA and RNA.
The Illumina DNA Prep is a fast, user-friendly solution for a wide range of applications from human whole-genome sequencing to amplicons, plasmids, and microbial species.
The iSeq 100 Sequencing System makes next-generation sequencing easier and more affordable than ever. Designed for simplicity, it allows labs of all sizes to sequence DNA and RNA at the push of a button.
The ECCMID 2022 Symposium is now available. Learn about metagenomics, genomic surveillance, microbiomes, and next-generation sequencing for tuberculosis.Watch video
In this featured article, read how Dr. Camilla Rodrigues is using NGS to fight MDR-TB at the P.D. Hinduja Hospital and Medical Research Centre in Mumbai, India.
Read the interview with Dr. Supply, who discusses the growing problem of MDR-TB, the values that Illumina next-generation sequencing (NGS) systems bring to their detection, and more.
Read what the scientific lead at South Africa’s Centre for Tuberculosis in Johannesburg believes when it comes to detecting and tracking MDR-TB using next-generation sequencing.
In this webinar, Dr. Arryn Craney, discusses integration options for NGS in microbiology clinical research and her recent hands-on experience with the Respiratory Pathogen ID/AMR Enrichment Panel (RPIP) Kit. In addition, this webinar explores future possibilities for advanced diagnostics.
World TB Day commemorates the day Dr. Robert Koch announced the bacterium responsible for TB in 1882. This day raises public awareness about the devastating impact TB continues to have and the challenges that lay ahead as we drive toward control and prevention.